02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

Cardiovascular disease INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting the MAP4K3- KLF2 / KLF4 pathway could help treat cerebral cavernous malformations (CCMs), which involve the formation of highly dilated blood vessels and symptoms...